This technology is two methods, called ssg-MeDIP-Seq and sscf-MeDIP-Seq, for improved tumor detection using detection of DNA methylation density in genomic DNA, and of hemi-methylated regions in plasma cell-free DNA.
Cancer detection is a critical component of the diagnosis and therapeutic pipeline. Biomarker detection offers a promising method of detection, offering an accessible and less-invasive alternative to more conventional diagnostic tools. Still, a highly precise and accessible tool to assess biomarkers that harnesses the full potential of information attainable for DNA samples has yet to emerge. A highly precise biomarker tool for cancer tumor detection, as well as classification will improve on the current standard of diagnosis.
This technology detects sDNA methylation density as well as hemi-methylated regions of genomic DNA and plasma cell free (cf) DNA to detect tumors. Quantification of genomic DNA methylation is a commonly used tool for tumor detection, however the use of detection of hemi-methylated DNA has not been robustly used. This technology uses the detection of differentially methylated regions (DMRs) and differentially hemi-methylated regions (DHMRs) as independent biomarkers for tumor detection.
This technology has been validated using human methylomes from 221 cfDNA samples.
IR CU24002
Licensing Contact: Joan Martinez
